Skip to main navigation Skip to search Skip to main content

Bortezomib as therapy for mixed humoral and cellular rejection: should it be first line?

  • Iris Lee
  • , Serban Constantinescu
  • , Avrum Gillespie
  • , Abhishek Swami
  • , Mark Birkenbach
  • , Stephen Leech
  • , Patricio Silva
  • , Andreas Karachristos
  • , John A. Daller
  • , Nicole M. Sifontis

Research output: Contribution to journalArticlepeer-review

Original languageEnglish (US)
Pages (from-to)425-429
Number of pages5
JournalClinical transplants
StatePublished - 2009
Externally publishedYes

Cite this